NGENLA® Dosage and Administration

(somatrogon-ghla)

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosing and Administration Information

•
NGENLA treatment should be supervised by a healthcare provider who is experienced in the diagnosis and management of pediatric patients aged 3 years and older with growth failure due to growth hormone deficiency (GHD) [see Indications and Usage (1)].
•
Refer patient to the Instructions for Use for complete administration instructions.
•
Administer NGENLA by subcutaneous injection, once weekly, on the same day each week, at any time of the day in the abdomen, thighs, buttocks, or upper arms. Rotate the injection site weekly.
•
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If flakes, particles or discoloration are observed, do not use the pen. Do not shake; shaking can damage the product.
•
Prefilled pens deliver somatrogon-ghla in 0.2 mg or 0.5 mg increments.

2.2 Perform Fundoscopic Examination Prior to Initiation of NGENLA

•
Perform fundoscopic examination before initiating treatment with NGENLA to exclude preexisting papilledema. If papilledema is identified, evaluate the etiology and treat the underlying cause before initiating treatment with NGENLA [see Warnings and Precautions (5.4)].

2.3 Recommended Dosage and Monitoring for Pediatric Patients with GHD

•
Recommended dosage of NGENLA is 0.66 mg/kg based on actual body weight administered once weekly by subcutaneous (SC) injection.
•
Individualize dosage for each patient based on the growth response.
•
The day of weekly administration can be changed if necessary as long as the time between 2 doses is at least 3 days. After selecting a new dosing day, the once weekly dosing should be continued.
•
When switching from daily growth hormone, the once-weekly NGENLA may be initiated on the day following their last daily injection.
•
If more than one injection is required to deliver a complete dose, each injection should be administered at a different injection site.

2.4 Missed Dose

•
If a dose is missed, administer NGENLA as soon as possible within 3 days after the missed dose.
•
If more than 3 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.

Find NGENLA® medical information:

Find NGENLA® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

NGENLA® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Dosage and Administration

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosing and Administration Information

•
NGENLA treatment should be supervised by a healthcare provider who is experienced in the diagnosis and management of pediatric patients aged 3 years and older with growth failure due to growth hormone deficiency (GHD) [see Indications and Usage (1)].
•
Refer patient to the Instructions for Use for complete administration instructions.
•
Administer NGENLA by subcutaneous injection, once weekly, on the same day each week, at any time of the day in the abdomen, thighs, buttocks, or upper arms. Rotate the injection site weekly.
•
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If flakes, particles or discoloration are observed, do not use the pen. Do not shake; shaking can damage the product.
•
Prefilled pens deliver somatrogon-ghla in 0.2 mg or 0.5 mg increments.

2.2 Perform Fundoscopic Examination Prior to Initiation of NGENLA

•
Perform fundoscopic examination before initiating treatment with NGENLA to exclude preexisting papilledema. If papilledema is identified, evaluate the etiology and treat the underlying cause before initiating treatment with NGENLA [see Warnings and Precautions (5.4)].

2.3 Recommended Dosage and Monitoring for Pediatric Patients with GHD

•
Recommended dosage of NGENLA is 0.66 mg/kg based on actual body weight administered once weekly by subcutaneous (SC) injection.
•
Individualize dosage for each patient based on the growth response.
•
The day of weekly administration can be changed if necessary as long as the time between 2 doses is at least 3 days. After selecting a new dosing day, the once weekly dosing should be continued.
•
When switching from daily growth hormone, the once-weekly NGENLA may be initiated on the day following their last daily injection.
•
If more than one injection is required to deliver a complete dose, each injection should be administered at a different injection site.

2.4 Missed Dose

•
If a dose is missed, administer NGENLA as soon as possible within 3 days after the missed dose.
•
If more than 3 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.